利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

221 条记录 (耗时 0.045 秒)

    Hepatocytes for therapy and drug screening made from embryonic stem cells
    24.
    发明授权
    Hepatocytes for therapy and drug screening made from embryonic stem cells 有权
    用胚胎干细胞进行治疗和药物筛选的肝细胞

    公开(公告)号：US07282366B2

    公开(公告)日：2007-10-16

    申请号：US10087142

    申请日：2002-03-01

    申请人： Lakshmi Rambhatla ,  Melissa K. Carpenter

    发明人： Lakshmi Rambhatla ,  Melissa K. Carpenter

    IPC分类号： C12N5/00 ,  C12N5/02 ,  C12N5/06 ,  C12N5/10 ,  C12N5/08

    CPC分类号： C12N5/067 ,  C12N2500/30 ,  C12N2500/36 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/12 ,  C12N2501/148 ,  C12N2501/33 ,  C12N2501/335 ,  C12N2501/385 ,  C12N2501/39 ,  C12N2503/02 ,  C12N2506/02 ,  C12N2533/92

    摘要： It has been discovered that when pluripotent stem cells are cultured in the presence of a hepatocyte differentiation agent, a population of cells is derived that has a remarkably high proportion of cells with phenotypic characteristics of liver cells. In one example, human embryonic stem cells are allowed to form embryoid bodies, and then combined with the differentiation agent n-butyrate, optionally supplemented with maturation factors. In another example, n-butyrate is added to human embryonic stem cells in feeder-free culture. Either way, a remarkably uniform cell population is obtained, which is predominated by cells with morphological features of hepatocytes, expressing surface markers characteristic of hepatocytes, and having enzymatic and biosynthetic activity important for liver function. Since stem cells readily proliferate in culture, this system provides an abundant source of cells of the hepatocyte lineage for a variety of applications, such as drug screening, and replenishing liver function in the context of clinical treatment.

    摘要翻译： 已经发现，当在肝细胞分化剂存在下培养多能干细胞时，衍生出具有非常高比例的具有肝细胞表型特征的细胞的细胞群。 在一个实例中，允许人胚胎干细胞形成胚状体，然后与分选剂正丁酸酯组合，任选地补充成熟因子。 在另一个实例中，在无饲养细胞培养物中将正丁酸加入到人胚胎干细胞中。 无论哪种方式，获得了显着均匀的细胞群，其由具有肝细胞形态特征的细胞占主导，表达肝细胞特征的表达标志物，并具有对肝功能重要的酶和生物合成活性。 由于干细胞在培养物中容易增殖，所以该系统为各种应用提供了丰富的肝细胞谱系来源，如药物筛选，并在临床治疗的背景下补充肝功能。

    Treatment for wounds
    25.
    发明授权
    Treatment for wounds 有权
    治疗伤口

    公开(公告)号：US07262174B2

    公开(公告)日：2007-08-28

    申请号：US10143536

    申请日：2002-05-09

    申请人： Xu-Rong Jiang ,  Choy-Pik Chiu ,  Calvin B. Harley

    发明人： Xu-Rong Jiang ,  Choy-Pik Chiu ,  Calvin B. Harley

    IPC分类号： A61K48/00

    CPC分类号： A61L26/0066 ,  A61K35/12 ,  A61K35/36 ,  A61K38/45 ,  A61L15/40 ,  A61L15/44 ,  A61L27/3804 ,  A61L27/3813 ,  A61L2300/258 ,  A61L2300/412 ,  C12N5/0629 ,  C12N2510/04 ,  C12N2799/022 ,  C12N2799/027

    摘要： It has been discovered that increasing telomerase activity in cells surrounding a wound has a variety of effects that enhance wound healing. Replication capacity is enhanced, and the mobility of the epithelial cells can be increased by 3-fold or more. Some aspects of the invention relate to agents that increase telomerase activity in cells at the site of the wound, promoting cells to move to the site and restore an epithelial layer and the underlying stratum. Other aspects of the invention relate to compositions comprising epithelial cells in which telomerase activity has been increased, useful as grafts for the treatment of wounds.

    摘要翻译： 已经发现，在伤口周围的细胞中增加端粒酶活性具有增强伤口愈合的各种效果。 复制能力增强，上皮细胞的迁移率可以提高3倍以上。 本发明的一些方面涉及在伤口部位的细胞中增加端粒酶活性的试剂，促进细胞移动到位点并恢复上皮层和下层。 本发明的其它方面涉及包含其中端粒酶活性增加的上皮细胞的组合物，可用作治疗伤口的移植物。

    Process for making hepatocytes from pluripotent stem cells
    26.
    发明授权
    Process for making hepatocytes from pluripotent stem cells 有权
    从多能干细胞制备肝细胞的方法

    公开(公告)号：US07256042B2

    公开(公告)日：2007-08-14

    申请号：US10001267

    申请日：2001-10-31

    申请人： Lakshmi Rambhatla ,  Melissa K. Carpenter

    发明人： Lakshmi Rambhatla ,  Melissa K. Carpenter

    IPC分类号： C12N5/00 ,  C12N5/08 ,  C12N5/02

    CPC分类号： C12N5/067 ,  C12N2500/30 ,  C12N2500/36 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/12 ,  C12N2501/148 ,  C12N2501/33 ,  C12N2501/335 ,  C12N2501/385 ,  C12N2501/39 ,  C12N2503/02 ,  C12N2506/02 ,  C12N2533/90 ,  C12N2533/92

    摘要： It has been discovered that when pluripotent stem cells are cultured in the presence of a hepatocyte differentiation agent, a population of cells is derived that has a remarkably high proportion of cells with phenotypic characteristics of liver cells. In one example, human embryonic stem cells are allowed to form embryoid bodies, and then combined with the differentiation agent n-butyrate, optionally supplemented with maturation factors. In another example, n-butyrate is added to human embryonic stem cells in feeder-free culture. Either way, a remarkably uniform cell population is obtained, which is predominated by cells with morphological features of hepatocytes, expressing surface markers characteristic of hepatocytes, and having enzymatic and biosynthetic activity important for liver function. Since stem cells readily proliferate in culture, this system provides an abundant source of cells of the hepatocyte lineage for a variety of applications, such as drug screening, and replenishing liver function in the context of clinical treatment.

    摘要翻译： 已经发现，当在肝细胞分化剂存在下培养多能干细胞时，衍生出具有非常高比例的具有肝细胞表型特征的细胞的细胞群。 在一个实例中，允许人胚胎干细胞形成胚状体，然后与分选剂正丁酸酯组合，任选地补充成熟因子。 在另一个实例中，在无饲养细胞培养物中将正丁酸加入到人胚胎干细胞中。 无论哪种方式，获得了显着均匀的细胞群，其由具有肝细胞形态特征的细胞占主导，表达肝细胞特征的表达标志物，并具有对肝功能重要的酶和生物合成活性。 由于干细胞在培养物中容易增殖，所以该系统为各种应用提供了丰富的肝细胞谱系来源，如药物筛选，并在临床治疗的背景下补充肝功能。

    Marker system for preparing and characterizing high-quality human embryonic stem cells
    27.
    发明授权
    Marker system for preparing and characterizing high-quality human embryonic stem cells 有权
    用于制备和表征高质量人类胚胎干细胞的标记系统

    公开(公告)号：US07153650B2

    公开(公告)日：2006-12-26

    申请号：US10389431

    申请日：2003-03-13

    申请人： Lawrence W. Stanton ,  Ralph Brandenberger ,  Joseph D. Gold ,  John M. Irving ,  Ramkumar Mandalam ,  Michael Mok

    发明人： Lawrence W. Stanton ,  Ralph Brandenberger ,  Joseph D. Gold ,  John M. Irving ,  Ramkumar Mandalam ,  Michael Mok

    IPC分类号： C12Q1/00 ,  C12Q1/68 ,  G01N33/53 ,  C12N5/00 ,  C12N5/02

    CPC分类号： C12Q1/6881 ,  C12Q2600/158 ,  G01N33/5005

    摘要： This disclosure provides a system for qualifying embryonic stem cells intended for human therapy. A large-scale sequencing project has identified important markers that are characteristic of undifferentiated pluripotent cells. Combinations of these markers can be used to validate the self-renewing capacity of ES cells, and their ability to differentiate into tissue types suitable for regenerative medicine. The marker system of this invention has been used to screen feeder cells, media additives, and culture conditions that promote proliferation of stem cells without differentiation. A culture system optimized by following these markers is suitable for rapid expansion of undifferentiated cells from existing lines, or the derivation of new lines that are equally apposite for clinical use.

    摘要翻译： 本公开提供了用于限定用于人类治疗的胚胎干细胞的系统。 大规模测序项目确定了未分化多能细胞特征的重要标志物。 这些标记的组合可以用于验证ES细胞的自我更新能力，以及它们分化成适合再生医学的组织类型的能力。 本发明的标记系统已用于筛选不分化促进干细胞增殖的饲养细胞，培养基添加剂和培养条件。 通过遵循这些标记优化的培养系统适用于从现有品系中未分化细胞的快速扩增，或适用于临床应用的新品系的衍生。

    Animal tissue with carbohydrate antigens compatible for human transplantation
    28.
    发明授权
    Animal tissue with carbohydrate antigens compatible for human transplantation 有权
    具有与人类移植相容的碳水化合物抗原的动物组织

    公开(公告)号：US07126039B2

    公开(公告)日：2006-10-24

    申请号：US10105963

    申请日：2002-03-21

    申请人： Chris Denning ,  A. John Clark ,  J. Michael Schiff

    发明人： Chris Denning ,  A. John Clark ,  J. Michael Schiff

    IPC分类号： A01K67/027 ,  C12N15/00 ,  C12N5/00

    CPC分类号： A01K67/0276 ,  A01K67/0271 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/02 ,  A01K2267/025 ,  A61K2035/122 ,  C12N9/1051 ,  C12N9/1276 ,  C12N15/8509 ,  C12N15/873 ,  C12N2517/02 ,  C12N2517/04 ,  C12N2517/10 ,  C12N2800/108 ,  C12N2800/30

    摘要： This disclosure provides a system for generating animal tissue with carbohydrate antigens that are compatible for transplantation into human patients. The tissue is inactivated homozygously for expression of α(1,3)galactosyltransferase, and comprises a transgene for α(1,2)fucosyltransferase. As a result, cell-surface N-acetyl lactosamine is not converted to the Galα(1,3)Gal xenoantigen. Instead, it is converted to Fucα(1,2)Gal, which is H substance, a self-antigen in humans. The tissue may also contain A or B-transferase, which will cause H substance to be converted into other ABO blood group antigens for compatibility with patients of the same blood type. This invention improves transplant compatibility of the xenograft tissue by lessening the risk of reactions resulting from xenoantigen and unconverted N-acetyl lactosamine acceptor determinants.

    摘要翻译： 本公开提供了一种用于产生具有与人类患者移植相容的碳水化合物抗原的动物组织的系统。 组织对于α（1,3）半乳糖基转移酶的表达是纯合的，并且包含α（1,2）岩藻糖基转移酶的转基因。 结果，细胞表面N-乙酰乳糖胺不转化为Galalpha（1,3）Gal异种抗原。 相反，它被转化为人类中的自身抗原的Fucalpha（1,2）Gal，它是H物质。 组织还可以含有A或B转移酶，这将导致H物质转化成其他ABO血型抗原，以与相同血型的患者相容。 本发明通过减轻由异种抗原和未转化的N-乙酰乳糖胺受体决定簇产生的反应的风险来改善异种移植物组织的移植物相容性。